REDWOOD CITY, Calif. — November 11, 2025 — Leads & Copy — Soleno Therapeutics, Inc. (NASDAQ: SLNO) has announced a share repurchase program, authorizing its Board of Directors to repurchase $100 million of the company’s common stock. Soleno has entered into an Accelerated Share Repurchase Agreement (ASR) with Jefferies LLC to facilitate the repurchase.
Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics, stated that the actions reflect confidence in the commercial launch of VYKAT XR and its potential as a foundational therapy for patients with hyperphagia associated with Prader-Willi syndrome. Bhatnagar added that profitability was achieved in the third quarter of 2025 and that the business’s expected future cash generation is undervalued by the capital markets, making the share repurchase a compelling opportunity.
Under the ASR agreement, Soleno will make an initial payment of $100 million, receiving an initial delivery of approximately 1,511,553 shares based on the closing price on November 10, 2025. The final number of shares repurchased will be determined by the average volume-weighted price of Soleno’s common stock during the ASR term, subject to adjustments as per the agreement. The ASR is expected to be completed in the first quarter of 2026.
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Source: Soleno Therapeutics, Inc.
